Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study

Oncologist

Volumn 18, Issue 3, 2013, Pages 257-264

  Swain, Sandra M ^a   Ewer, Michael S ^b   Cortés, Javier ^c   Amadori, Dino ^d   Miles, David ^e   Knott, Adam ^f   Clark, Emma ^f   Benyunes, Mark C ^g   Ross, Graham ^f   Baselga, José ^h  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g GENENTECH INC   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cardiac safety; HER2; LVSD; Metastatic breast cancer; Pertuzumab; Trastuzumab

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; PLACEBO; TRASTUZUMAB;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BRADYCARDIA; BREAST METASTASIS; CARDIOMEGALY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; INCIDENCE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MITRAL VALVE REGURGITATION; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PERICARDITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SMOKING; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; STROKE VOLUME; TAXOIDS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84875421601     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0448     Document Type: Article

References (36)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressesHER2. N Engl J Med 2001;344:783-792.
2. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
5. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221.
6. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-329.
7. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003; 97:2869-2879.
8. Lefrak EA, Pitha J, Rosenheim S et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
9. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
10. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905.
11. Kotamraju S, Konorev EA, Joseph J et al. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000;275: 33585-33592.
12. Billingham ME, Mason JW, Bristow MR et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-872.
13. Mackay B, Ewer MS, Carrasco CH et al. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 1994;18: 203-211.
14. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13:173-183.
15. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 2005;23:2900-2902.
16. Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23: 7811-7819.
17. Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007;25: 3859-3865.
18. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-7826.
19. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115.
20. Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378:394-398.
21. Erickson SL, O'Shea KS, Ghaboosi N et al. ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2-and heregulin-deficient mice. Development 1997;124:4999-5011.
22. Zhao YY, Sawyer DR, Baliga RR et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998;273:10261-10269.
23. Chien KR. Stress pathways and heart failure. Cell 1999;98:555-558.
24. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Rec Prog Horm Res 2004;59:1-12.
25. Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-760.
26. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-328.
27. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137.
28. Lenihan D, Suter T, Brammer M et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012;23:791-800.
29. Baselga J, Cortes J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
30. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
31. Portera CC, Walshe JM, Rosing DR et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14: 2710-2716.
32. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-1144.
33. Cortes J, Fumoleau P, Bianchi GV et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30: 1594-1600.
34. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
35. Schneeweiss A, Chia S, Hickish T et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: A randomized phase II study (TRYPHAENA). Cancer Res 2011;71(24 suppl):S5-6.
36. Swain SM, Kim S-B, Cortes J et al. Confirmatory overall survival analysis of CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive first-line metastatic breast cancer. Cancer Res 2012;72(24 suppl):P5-18-26